SEC Form 4 · accession 0000899243-18-024025
AILERON THERAPEUTICS INC · ALRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Manuel Aivado
Officer — President and CEO · Director
Period of report
Sep 6, 2018
Accepted (ET)
Sep 7, 2018 · 5:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001420565
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.39 | Sep 6, 2018 | A | 232,914 | A | — | Sep 5, 2028 | Common Stock | 232,914 | 232,914 | D |
Explanation of responses
- F1This option was granted on September 6, 2018. The shares underlying the option are scheduled to vest in equal monthly installments over four years from September 6, 2018.